A thin hypointense line or small dot at or near the center of most MRI lesions can help differentiate MS from other autoimmune diseases.
To reveal veins in the central nervous system (CNS), susceptibility-weighted MRI is useful by virtue of showing deoxyhemoglobin as a hypointense signal. Prior studies have consistently demonstrated hypointense venules within the white matter lesions characteristic of multiple sclerosis (MS). Now, investigators have evaluated this “central vein sign” as a specific marker of demyelinating disease compared with systemic inflammatory or autoimmune diseases (SADs) such as systemic lupus erythematosus, antiphospholipid syndrome, Sjögren syndrome, and primary angiitis of the CNS.
Median number of MRI lesions was 15 in both relapsing remitting MS (52 patients) and SADs (31 patients), but median lesion volume was 34% smaller in patients with SADs. Le…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)